RU2005119305A - Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2 - Google Patents
Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2 Download PDFInfo
- Publication number
- RU2005119305A RU2005119305A RU2005119305/13A RU2005119305A RU2005119305A RU 2005119305 A RU2005119305 A RU 2005119305A RU 2005119305/13 A RU2005119305/13 A RU 2005119305/13A RU 2005119305 A RU2005119305 A RU 2005119305A RU 2005119305 A RU2005119305 A RU 2005119305A
- Authority
- RU
- Russia
- Prior art keywords
- variable region
- antibody
- fusion protein
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/467—Igs with modifications in the FR-residues only
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Claims (25)
1. Вариабельная область антитела, содержащая последовательность аминокислот, представленную как SEQ ID NO:1.
2. Вариабельная область антитела, содержащая последовательность аминокислот, представленную как SEQ ID NO:2.
3. Вариабельная область антитела по п.2, отличающаяся тем, что она дополнительно содержит последовательность аминокислот, представленную как SEQ ID N0:1.
4. Вариабельная область антитела по п.3, отличающаяся тем, что последовательности аминокислот соединены дисульфидной связью.
5. Вариабельная область антитела по п.3, отличающаяся тем, что последовательности аминокислот соединены пептидной связью.
6. Вариабельная область антитела, содержащая последовательность аминокислот, выбранную из группы, состоящей из аминокислот 1-23 последовательности SEQ ID NO:1, аминокислот 1-25 последовательности SEQ ID NO:2 и аминокислот 67-98 последовательности SEQ ID NO:2, характеризующаяся тем, что Вариабельная область антитела специфически связывается с GD2.
7. Вариабельная область антитела по п.6, отличающаяся тем, что последовательность аминокислот включает аминокислоты 1-23 последовательности SEQ ID NO:1.
8. Вариабельная область антитела по п.6, отличающаяся тем, что последовательность аминокислот включает аминокислоты 1-25 последовательности SEQ ID NO:2.
9. Вариабельная область антитела по п.6, отличающаяся тем, что последовательность аминокислот включает аминокислоты 67-98 последовательности SEQ ID NO:2.
10. Полипептид, содержащий вариабельную область антитела, как она определена в любом из предшествующих пунктов и Fc-фрагмент, содержащий, по меньшей мере, один СН2 домен.
11. Полипептид по п.10, отличающийся тем, что Fc-фрагмент получен из IgG1.
12. Нуклеиновая кислота, кодирующая вариабельную область антитела по любому из пп.1-9 или полипептид по п.10 или 11.
13. Клетка, содержащая нуклеиновую кислоту по п.12.
14. Способ нацеливания на клетку, несущую на поверхности GD2, включающий: введение вариабельной области антитела по любому из пп.1-9 или полипептида по п.10 или 11.
15. Способ по п.14, отличающийся тем, что клетка является опухолевой клеткой.
16. Слитый белок, содержащий вариабельную область антитела по любому из пп.1-9 или полипептид по п.10 или 11, соединенные с неиммуноглобулиновой частью.
17. Слитый белок по п.16, отличающийся тем, что неиммуноглобулиновая часть является цитокином.
18. Слитый белок по п.17, отличающийся тем, что цитокин выбран из группы, состоящей из интерлейкина, гематопоэтического фактора, лимфокина, интерферона и хемокина.
19. Слитый белок по п.18, отличающийся тем, что интерлейкин выбран из группы, состоящей из интерлейкина-2 (IL-2) и интерлейкина-12 (IL-12).
20. Слитый белок по п.18, отличающийся тем, что гематопоэтический фактор является гранулоцитарно-макрофагальным колониестимулирующим фактором (GM-CSF).
21. Слитый белок по п.18, отличающийся тем, что лимфокин является лимфотоксином.
22. Слитый белок по п.18, отличающийся тем, что интерферон выбран из группы, состоящей из интерферона-α, интерферона-β и интерферона-γ.
23. Слитый белок по п.16, отличающийся тем, что он дополнительно содержит вторую неиммуноглобулиновую часть.
24. Слитый белок по п.23, отличающийся тем, что слитый белок содержит IL-2 и IL-12.
25. Применение нуклеиновой кислоты по п.12 или клетки по пункту 13 для производства медикамента.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43394502P | 2002-12-17 | 2002-12-17 | |
US60/433,945 | 2002-12-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2005119305A true RU2005119305A (ru) | 2006-01-20 |
RU2366664C2 RU2366664C2 (ru) | 2009-09-10 |
Family
ID=32595250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005119305/13A RU2366664C2 (ru) | 2002-12-17 | 2003-12-16 | Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2 |
Country Status (18)
Country | Link |
---|---|
US (3) | US7169904B2 (ru) |
EP (1) | EP1572748B1 (ru) |
JP (1) | JP4494977B2 (ru) |
KR (1) | KR101086660B1 (ru) |
CN (1) | CN100432105C (ru) |
AT (1) | ATE471946T1 (ru) |
AU (1) | AU2003298187B2 (ru) |
BR (1) | BRPI0317376B8 (ru) |
CA (1) | CA2510180C (ru) |
DE (1) | DE60333121D1 (ru) |
DK (1) | DK1572748T3 (ru) |
ES (1) | ES2346205T3 (ru) |
MX (1) | MXPA05006384A (ru) |
PL (1) | PL211180B1 (ru) |
PT (1) | PT1572748E (ru) |
RU (1) | RU2366664C2 (ru) |
WO (1) | WO2004055056A1 (ru) |
ZA (1) | ZA200505681B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2689388C1 (ru) * | 2013-12-16 | 2019-05-28 | Дженентек, Инк. | Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2693296C (en) * | 1997-12-08 | 2013-09-10 | Merck Patent Gmbh | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
DK1294401T3 (da) * | 2000-06-29 | 2007-10-08 | Merck Patent Gmbh | Forbedring af antistof/cytokin-fusionsproteinmedierede immunresponser ved kombineret behandling med immuncytokin-optagelsesforberende midler |
CA2440221C (en) * | 2001-03-07 | 2013-02-05 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Expression technology for proteins containing a hybrid isotype antibody moiety |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
PL205352B1 (pl) * | 2001-05-03 | 2010-04-30 | Merck Patent Gmbh | Rekombinowane przeciwciało specyficzne dla nowotworu |
EP1454138B1 (en) * | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
US9371559B2 (en) | 2002-06-20 | 2016-06-21 | The Regents Of The University Of California | Compositions for detection and analysis of polynucleotides using light harvesting multichromophores |
US10001475B2 (en) | 2002-06-20 | 2018-06-19 | The Regents Of The University Of California | Light harvesting multichromophore compositions and methods of using the same |
RU2366664C2 (ru) * | 2002-12-17 | 2009-09-10 | Мерк Патент Гмбх | Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2 |
JP4740111B2 (ja) * | 2003-02-13 | 2011-08-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 集光性多発色団を用いてポリヌクレオチド結合タンパク質相互作用を検出及び分析するための方法並びに組成物 |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
EP1533617A1 (en) | 2003-11-19 | 2005-05-25 | RMF Dictagene S.A. | Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer |
US7642341B2 (en) | 2003-12-18 | 2010-01-05 | Merck Serono S.A. | Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer |
EP1699822B1 (en) * | 2003-12-30 | 2008-04-23 | MERCK PATENT GmbH | Il-7 fusion proteins with antibody portions, their preparation and their use |
KR20060124656A (ko) * | 2003-12-31 | 2006-12-05 | 메르크 파텐트 게엠베하 | 개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질 |
EP1706428B1 (en) * | 2004-01-22 | 2009-09-23 | MERCK PATENT GmbH | Anti-cancer antibodies with reduced complement fixation |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
KR20070085886A (ko) | 2004-12-09 | 2007-08-27 | 메르크 파텐트 게엠베하 | 감소된 면역원성의 il-7 변이체 |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
ES2384055T3 (es) * | 2005-12-30 | 2012-06-28 | Merck Patent Gmbh | Variantes de la interleucina-12p40 con estabilidad mejorada |
ES2365046T3 (es) | 2005-12-30 | 2011-09-21 | Merck Patent Gmbh | Anticuerpos anti-cd19 con inmunogenicidad reducida. |
ES2424468T3 (es) * | 2006-03-27 | 2013-10-02 | Medimmune Limited | Miembro de unión para el receptor GM-CSF |
US7787618B2 (en) | 2006-03-29 | 2010-08-31 | Nokia Corporation | Portable electronic device |
JP2009542592A (ja) * | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−2媒介性免疫応答の有効性を高める組成物および方法 |
AU2007301599B2 (en) | 2006-09-28 | 2013-01-10 | Merck Serono S.A. | Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use |
US20080287320A1 (en) * | 2006-10-04 | 2008-11-20 | Codon Devices | Libraries and their design and assembly |
FR2906808B1 (fr) * | 2006-10-10 | 2012-10-05 | Univ Nantes | Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers |
WO2009152901A1 (en) * | 2008-05-30 | 2009-12-23 | Merck Patent Gmbh, | Methods for treatment of malignancies |
WO2009149218A2 (en) * | 2008-06-03 | 2009-12-10 | Codon Devices, Inc. | Novel proteins and methods of designing and using same |
MX2010014364A (es) | 2008-06-30 | 2011-08-12 | Morphotek Inc | Anticuerpos anti-gd2 y metodos y usos relacionados con los mismos. |
WO2010117448A2 (en) * | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
EA201171259A1 (ru) * | 2009-04-22 | 2012-05-30 | Мерк Патент Гмбх | Антительные гибридные белки с модифицированными сайтами связывания fcrn |
RU2682720C2 (ru) * | 2010-01-19 | 2019-03-21 | Ханми Сайенс Ко., Лтд. | Жидкие составы для конъюгата эритропоэтина длительного действия |
PT2560658T (pt) | 2010-04-21 | 2017-05-26 | Ventirx Pharmaceuticals Inc | Citotoxicidade celular dependente de anticorpo intensificada |
CN102946858B (zh) * | 2010-05-10 | 2015-09-30 | 英塔斯制药有限公司 | 含有免疫球蛋白Fc的多肽的液体制剂 |
EP4269563A3 (en) | 2010-06-19 | 2024-01-10 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
US20120065092A1 (en) * | 2010-09-14 | 2012-03-15 | Wai Hobert | Fusion analyte cytometric bead assay, and systems and kits for performing the same |
KR101667096B1 (ko) | 2011-02-10 | 2016-10-18 | 로슈 글리카트 아게 | 돌연변이 인터루킨-2 폴리펩티드 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US11492383B2 (en) | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
EP4218811A1 (en) | 2012-06-18 | 2023-08-02 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US20160040212A1 (en) * | 2013-03-15 | 2016-02-11 | The Broad Institute, Inc. | Methods for the Detection of DNA-RNA Proximity in Vivo |
CN105705165B (zh) * | 2013-03-15 | 2020-04-24 | 纪念斯隆-凯特琳癌症中心 | 高亲和力抗gd2抗体 |
US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
CA2930285A1 (en) | 2013-11-21 | 2015-05-28 | Apeiron Biologics Ag | Preparations and methods for treating a gd2 positive cancer |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
GB201403972D0 (en) * | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
WO2017055385A1 (en) * | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xgd2 bispecific t cell activating antigen binding molecules |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
KR102396324B1 (ko) * | 2016-07-25 | 2022-05-09 | 위스콘신 얼럼나이 리서어치 화운데이션 | 인 시츄 면역 조절 암 백신화를 위한 표적화된 방사선요법 킬레이트 |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
CN108948211B (zh) * | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
RU2708136C1 (ru) * | 2019-04-15 | 2019-12-04 | Общество с ограниченной ответственностью "Реал Таргет" | Новые белковые конструкции для диагностики и терапии gd2-позитивных заболеваний |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (171)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4469797A (en) | 1982-09-23 | 1984-09-04 | Miles Laboratories, Inc. | Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
US5082658A (en) | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
EP0158198A1 (en) | 1984-03-29 | 1985-10-16 | Takeda Chemical Industries, Ltd. | DNA and use thereof |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4667016A (en) | 1985-06-20 | 1987-05-19 | Kirin-Amgen, Inc. | Erythropoietin purification |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US5679543A (en) | 1985-08-29 | 1997-10-21 | Genencor International, Inc. | DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi |
US5643565A (en) | 1985-09-20 | 1997-07-01 | Chiron Corporation | Human IL-2 as a vaccine adjuvant |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
DE3712985A1 (de) | 1987-04-16 | 1988-11-03 | Hoechst Ag | Bifunktionelle proteine |
US5359035A (en) | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
EP0237019A3 (en) | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Interferon conjugate and production thereof using recombinant gene |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DK173067B1 (da) | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
US4894227A (en) | 1986-08-01 | 1990-01-16 | Cetus Corporation | Composition of immunotoxins with interleukin-2 |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4844893A (en) * | 1986-10-07 | 1989-07-04 | Scripps Clinic And Research Foundation | EX vivo effector cell activation for target cell killing |
US5508031A (en) | 1986-11-21 | 1996-04-16 | Cetus Oncology Corporation | Method for treating biological damage using a free-radial scavenger and interleukin-2 |
US4732683A (en) | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
DE3853740T2 (de) | 1987-06-10 | 1995-11-09 | Dana Farber Cancer Inst Inc | Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen. |
US5064646A (en) | 1988-08-02 | 1991-11-12 | The University Of Maryland | Novel infectious bursal disease virus |
ATE88900T1 (de) | 1987-09-02 | 1993-05-15 | Ciba Geigy Ag | Konjugate von interferon alpha mit immunglobulinen. |
CA1338518C (en) | 1987-09-23 | 1996-08-13 | Joyce M. Zarling | Antibody heteroconjugates for the killing of hiv-infected cells |
NZ226414A (en) | 1987-10-02 | 1992-07-28 | Genentech Inc | Cd4 peptide adhesion variants and their preparation and use |
ZA888978B (en) | 1987-12-04 | 1990-07-25 | Du Pont | Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
CA1341588C (en) | 1988-01-26 | 2009-01-06 | Michel Revel | Human ifn-beta2/i1-6, its purification and use |
US5120525A (en) | 1988-03-29 | 1992-06-09 | Immunomedics, Inc. | Radiolabeled antibody cytotoxic therapy of cancer |
US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
IE62463B1 (en) | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
US5242824A (en) | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
DE69019609T2 (de) | 1989-07-07 | 1995-11-30 | Takeda Chemical Industries Ltd | Proteine und deren Herstellung. |
US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
US5196320A (en) * | 1989-09-20 | 1993-03-23 | Abbott Biotech, Inc. | Method of producing engineered binding proteins |
US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
WO1991005867A1 (en) | 1989-10-13 | 1991-05-02 | Amgen Inc. | Erythropoietin isoforms |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
ATE368112T1 (de) | 1989-12-22 | 2007-08-15 | Hoffmann La Roche | Zytotoxischer lymphozyten-reifefaktor 40kd untereinheit und monoklonale antikörper spezifisch dafür |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
AU649716B2 (en) * | 1990-09-18 | 1994-06-02 | Akzo N.V. | Copolymerization process and optical copolymer produced therefrom |
US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
FR2670039B1 (fr) * | 1990-11-29 | 1993-12-24 | Commissariat A Energie Atomique | Procede et dispositif de reconstruction d'images tridimentionnelles d'un objet en utilisant deux trajectoires circulaires d'acquisition. |
US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
US6072039A (en) | 1991-04-19 | 2000-06-06 | Rohm And Haas Company | Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
US6797492B2 (en) * | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
LU91067I2 (fr) * | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DE69227693T2 (de) | 1991-08-30 | 1999-07-22 | Hutchinson Fred Cancer Res | Hybride cytokine |
US20020037558A1 (en) | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
DE69228263T2 (de) * | 1991-11-25 | 1999-08-05 | Sharp Kk | Vorrichtung zur weiteren Bearbeitung von Kopien |
US6627615B1 (en) * | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
SK280610B6 (sk) | 1992-02-06 | 2000-05-16 | Schering Corporation | Monoklonálna a humanizovaná monoklonálna protilátk |
US5593874A (en) * | 1992-03-19 | 1997-01-14 | Monsanto Company | Enhanced expression in plants |
ATE260971T1 (de) | 1992-04-01 | 2004-03-15 | Univ Rockefeller | Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung |
ATE311895T1 (de) | 1992-05-26 | 2005-12-15 | Immunex Corp | Neue zytokine die cd30 binden |
WO1993024640A2 (en) | 1992-06-04 | 1993-12-09 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
EP0671926B1 (en) | 1992-08-11 | 2002-11-13 | President And Fellows Of Harvard College | Immunomodulatory peptides |
DE4228839A1 (de) | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Verfahren zum Nachweis und zur Bestimmung von Mediatoren |
US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
EP1757694A3 (en) | 1992-11-05 | 2008-02-27 | Sloan Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US5738849A (en) | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
US5543297A (en) | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
AU6816194A (en) | 1993-04-20 | 1994-11-08 | Robinson, William S. | Methods and materials for treatment of individuals infected with intracellular infectious agents |
US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
AU697453B2 (en) | 1993-04-29 | 1998-10-08 | Abbott Laboratories | Erythropoietin analog compositions and methods |
US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
CA2125763C (en) | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
GB2280171B (en) * | 1993-07-22 | 1996-12-18 | Cargo Unit Containers Ltd | Improvments in or relating to freight containers |
CN1057534C (zh) | 1993-08-17 | 2000-10-18 | 柯瑞英-艾格公司 | 促红细胞生成素类似物 |
AU703152B2 (en) * | 1994-01-25 | 1999-03-18 | Biogen Ma Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
CN1636594B (zh) | 1994-04-26 | 2012-08-29 | 儿童医学中心公司 | 血管生成抑制素和用于抑制血管生成的方法 |
CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
ATE208633T1 (de) | 1994-09-16 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US5935821A (en) * | 1995-01-17 | 1999-08-10 | Board Of Trustees Of The University Of Kentucky | Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
WO1996028548A1 (en) | 1995-03-10 | 1996-09-19 | Genentech, Inc. | Receptor activation by gas6 |
US5719266A (en) | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
HUP9802609A2 (hu) | 1995-06-30 | 1999-03-29 | Eli Lilly And Co. | A diabetes kezelésére szolgáló eljárás |
CA2225852C (en) * | 1995-06-30 | 2009-04-14 | Mochida Pharmaceutical Co., Ltd. | Anti-fas ligand antibody and assay method using the anti-fas ligand antibody |
US6406689B1 (en) | 1995-10-03 | 2002-06-18 | Frank W. Falkenberg | Compositions and methods for treatment of tumors and metastatic diseases |
US5854205A (en) | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6080409A (en) | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
CA2205757C (en) | 1996-05-30 | 2006-01-24 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii) |
US5922685A (en) | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
WO1998010070A1 (fr) * | 1996-09-02 | 1998-03-12 | Sumitomo Electric Industries, Ltd. | IMMUNOGLOBULINE HUMANISEE REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas OU L'UN DE SES FRAGMENTS ACTIFS ET REGION D'INDUCTION D'APOPTOSE PRENANT NAISSANCE DANS UN LIGAND Fas |
ATE218143T1 (de) * | 1996-09-03 | 2002-06-15 | Gsf Forschungszentrum Umwelt | Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität |
US6417337B1 (en) * | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
US5994104A (en) | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
US6100387A (en) | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
CA2284726A1 (en) | 1997-04-11 | 1998-10-22 | G.D. Searle & Co. | Antagonistic anti-avb3 integrin antibodies |
CA2290485C (en) * | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
CA2693296C (en) | 1997-12-08 | 2013-09-10 | Merck Patent Gmbh | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US20030105294A1 (en) | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
PL343486A1 (en) | 1998-04-17 | 2001-08-27 | Lexigen Pharm Corp | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
US6284536B1 (en) | 1998-04-20 | 2001-09-04 | The Regents Of The University Of California | Modified immunoglobin molecules and methods for use thereof |
WO1999058662A1 (fr) | 1998-05-14 | 1999-11-18 | Merck Patent Gmbh | Proteine fusionnee |
US6620382B1 (en) | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
CZ302303B6 (cs) | 1998-08-25 | 2011-02-16 | Merck Patent Gmbh | Homodimerní fúzní protein vykazující inhibicní aktivitu na angiogenezi, zpusob jeho produkce, molekula DNA a replikovatelný expresní vektor |
US6646113B1 (en) | 1998-09-17 | 2003-11-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants |
US6335176B1 (en) | 1998-10-16 | 2002-01-01 | Pharmacopeia, Inc. | Incorporation of phosphorylation sites |
CN1202128C (zh) | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | 修饰蛋白的免疫原性 |
CA2356401A1 (en) | 1999-01-07 | 2000-07-13 | Lexigen Pharmaceuticals, Corp. | Expression and export of anti-obesity proteins as fc fusion proteins |
KR100816572B1 (ko) * | 1999-04-28 | 2008-03-24 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 항-vegf 항체 및 이를 포함하는 약제학적 조성물 |
AU4700100A (en) | 1999-05-06 | 2000-11-21 | Wake Forest University | Compositions and methods for identifying antigens which elicit an immune response |
US6348192B1 (en) | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
CZ20014123A3 (cs) | 1999-05-19 | 2002-06-12 | Lexigen Pharmaceuticals Corp. | Exprese a export interferonů-alfa jako Fc fúzních proteinů |
CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
RU2263118C2 (ru) * | 1999-08-09 | 2005-10-27 | Лексиген Фармасьютикэлс Корп. | Комплексы антител с несколькими цитокинами |
WO2001023573A1 (fr) * | 1999-09-30 | 2001-04-05 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps transplantes a domaine de determination de complementation de type humain, dresse contre le ganglioside gd2, et derive de cet anticorps |
JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
DE60121733T2 (de) | 2000-02-24 | 2007-08-09 | Philogen S.P.A. | Zusamensetzungen und Verfahren zur Behandlung von Angiogenese in pathologischen Schädigungen |
US6586398B1 (en) * | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
EP1285072A2 (en) | 2000-05-12 | 2003-02-26 | Neose Technologies, Inc. | In vitro fucosylation recombinant glycopeptides |
DK1294401T3 (da) | 2000-06-29 | 2007-10-08 | Merck Patent Gmbh | Forbedring af antistof/cytokin-fusionsproteinmedierede immunresponser ved kombineret behandling med immuncytokin-optagelsesforberende midler |
BR0116803A (pt) | 2001-01-18 | 2004-02-17 | Merck Patent Gmbh | Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase |
EP1361891A2 (en) * | 2001-02-19 | 2003-11-19 | MERCK PATENT GmbH | Artificial fusion proteins with reduced immunogenicity |
CA2440221C (en) | 2001-03-07 | 2013-02-05 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Expression technology for proteins containing a hybrid isotype antibody moiety |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
PL205352B1 (pl) | 2001-05-03 | 2010-04-30 | Merck Patent Gmbh | Rekombinowane przeciwciało specyficzne dla nowotworu |
EP1454138B1 (en) | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
US6996009B2 (en) * | 2002-06-21 | 2006-02-07 | Micron Technology, Inc. | NOR flash memory cell with high storage density |
RU2366664C2 (ru) | 2002-12-17 | 2009-09-10 | Мерк Патент Гмбх | Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2 |
US9395802B2 (en) | 2014-05-22 | 2016-07-19 | Via Alliance Semiconductor Co., Ltd. | Multi-core data array power gating restoral mechanism |
-
2003
- 2003-12-16 RU RU2005119305/13A patent/RU2366664C2/ru active
- 2003-12-16 EP EP03795898A patent/EP1572748B1/en not_active Expired - Lifetime
- 2003-12-16 JP JP2004560426A patent/JP4494977B2/ja not_active Expired - Lifetime
- 2003-12-16 ES ES03795898T patent/ES2346205T3/es not_active Expired - Lifetime
- 2003-12-16 US US10/737,208 patent/US7169904B2/en not_active Expired - Lifetime
- 2003-12-16 PL PL377337A patent/PL211180B1/pl unknown
- 2003-12-16 DE DE60333121T patent/DE60333121D1/de not_active Expired - Lifetime
- 2003-12-16 AT AT03795898T patent/ATE471946T1/de active
- 2003-12-16 MX MXPA05006384A patent/MXPA05006384A/es active IP Right Grant
- 2003-12-16 DK DK03795898.0T patent/DK1572748T3/da active
- 2003-12-16 CA CA2510180A patent/CA2510180C/en not_active Expired - Lifetime
- 2003-12-16 WO PCT/EP2003/014295 patent/WO2004055056A1/en active Application Filing
- 2003-12-16 CN CNB200380106522XA patent/CN100432105C/zh not_active Expired - Lifetime
- 2003-12-16 PT PT03795898T patent/PT1572748E/pt unknown
- 2003-12-16 BR BRPI0317376A patent/BRPI0317376B8/pt active IP Right Grant
- 2003-12-16 KR KR1020057011370A patent/KR101086660B1/ko active IP Right Grant
- 2003-12-16 AU AU2003298187A patent/AU2003298187B2/en not_active Expired
-
2005
- 2005-07-14 ZA ZA200505681A patent/ZA200505681B/en unknown
-
2006
- 2006-11-15 US US11/599,687 patent/US7767405B2/en active Active
-
2010
- 2010-04-27 US US12/768,678 patent/US8470991B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2689388C1 (ru) * | 2013-12-16 | 2019-05-28 | Дженентек, Инк. | Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами |
Also Published As
Publication number | Publication date |
---|---|
ATE471946T1 (de) | 2010-07-15 |
DK1572748T3 (da) | 2010-08-23 |
EP1572748A1 (en) | 2005-09-14 |
BRPI0317376B8 (pt) | 2021-05-25 |
US20100210831A1 (en) | 2010-08-19 |
WO2004055056A1 (en) | 2004-07-01 |
AU2003298187B2 (en) | 2010-09-16 |
AU2003298187A1 (en) | 2004-07-09 |
PT1572748E (pt) | 2010-09-28 |
CN1726227A (zh) | 2006-01-25 |
JP2006521085A (ja) | 2006-09-21 |
KR101086660B1 (ko) | 2011-11-24 |
BR0317376A (pt) | 2005-11-16 |
CN100432105C (zh) | 2008-11-12 |
PL377337A1 (pl) | 2006-01-23 |
JP4494977B2 (ja) | 2010-06-30 |
US20040203100A1 (en) | 2004-10-14 |
CA2510180C (en) | 2012-09-11 |
CA2510180A1 (en) | 2004-07-01 |
EP1572748B1 (en) | 2010-06-23 |
ZA200505681B (en) | 2006-04-26 |
PL211180B1 (pl) | 2012-04-30 |
KR20050085775A (ko) | 2005-08-29 |
US8470991B2 (en) | 2013-06-25 |
BRPI0317376B1 (pt) | 2019-12-03 |
US7767405B2 (en) | 2010-08-03 |
DE60333121D1 (de) | 2010-08-05 |
US7169904B2 (en) | 2007-01-30 |
US20070059282A1 (en) | 2007-03-15 |
ES2346205T3 (es) | 2010-10-13 |
MXPA05006384A (es) | 2005-08-29 |
RU2366664C2 (ru) | 2009-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2005119305A (ru) | Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2 | |
Bootz et al. | Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions | |
RU2263118C2 (ru) | Комплексы антител с несколькими цитокинами | |
ES2356620T3 (es) | Reducción de la inmunogenicidad de las proteínas de fusión. | |
EP1654287B1 (en) | Cd20-binding polypeptide compositions | |
Vazquez-Lombardi et al. | Molecular engineering of therapeutic cytokines | |
EP2201959A2 (en) | Use of IL-12 and IL-12 antagonists for the manufacture of a pharmaceutical composition for the treatment of autoimmune diseases | |
BG111719A (bg) | Методи за прилагане на анти-tnf алфа антитела | |
RU2007112929A (ru) | Способы применения лигандов рецептора смерти и антител к cd20 | |
CN1404400A (zh) | Il-18抑制剂的应用 | |
Schein | The shape of the messenger: using protein structure information to design novel cytokine-based therapeutics | |
JP2023509969A (ja) | 新規なマスクされたサイトカインおよびその使用方法 | |
WADHWA et al. | Production of neutralizing granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) antibodies in carcinoma patients following GM‐CSF combination therapy | |
Laricchia‐Robbio et al. | Naturally occurring and therapy‐induced antibodies to human granulocyte colony‐stimulating factor (G‐CSF) in human serum | |
Prümmer | Treatment-induced antibodies to interleukin-2 | |
US20110165122A1 (en) | Method for targeted and sustained antiviral therapy | |
Zdravkovic et al. | Physiology and pathology of cytokine: Commercial production and medical use | |
AU699913B2 (en) | Compositions and method for stimulating antibody release by B lymphocytes | |
Boraschi et al. | Interleukin-1 and interleukin-1 fragments as vaccine adjuvants | |
US6063371A (en) | Pharmaceutical compositions comprising a soluble interleukin-4 receptor | |
Xing et al. | Consideration of cytokines as therapeutics agents or targets | |
Balsari et al. | Natural antibodies to IL-2 | |
Revoltella et al. | Natural and therapy-induced anti-GM-CSF and anti-G-CSF antibodies in human serum | |
Ryff et al. | Interferons and interleukins | |
KR20230070256A (ko) | 이중특이성 재조합 단백질 및 이의 용도 |